Key result
Existing VTE risk scales fail to accurately predict thrombotic events in lymphoproliferative diseases.
Why the study?
Malignant lymphomas are often complicated by venous thromboembolism, but current risk scales used to guide thromboprophylaxis are imperfect.
Optimization of VTEC risk scales can improve the efficacy of anticoagulant therapy and decrease the incidence of thrombotic events in patients with malignant lymphomas.
Current VTE scales may underperform in lymphoproliferative diseases; leaves open whether hemostasis biomarkers can improve risk stratification.
The incidence of malignant lymphomas has been increasing in recent years worldwide. These diseases are often accompanied by venous thromboembolic complications (VTEC). The development of VTEC leads to interrupting of therapy, increasing mortality and significant rising of treatment costs. Anticoagulants are effective in VTEC prophylaxis. Prescribing of anticoagulant therapy is based on VTEC different risk scales, which are far from perfect. The search of additional features for hemostasis assessment can increase the prognostic value of these scales. The optimization of VTEC risk scales can improve efficacy of anticoagulant therapy and decrease an incidence of thrombotic events in patient with malignant lymphomas. The article presents a literature review and own clinical observations regarding the VTEC risk assessment in patients with lymphoproliferative diseases.
No takes yet. Share an insight, caveat, or question.
Ignatiev et al. (2022) conducted a review in Lymphoproliferative diseases. Venous thromboembolism risk assessment scales was evaluated on Venous thromboembolic complications. Existing venous thromboembolism risk assessment scales often fail to accurately predict thrombotic events in patients with lymphoproliferative diseases, suggesting a need for additional hemostasis biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: